Betta Net Income From Continuing Ops from 2010 to 2024

300558 Stock   49.36  3.74  7.04%   
Betta Pharmaceuticals' Net Income From Continuing Ops is decreasing over the years with stable fluctuation. Net Income From Continuing Ops is expected to dwindle to about 248 M. From 2010 to 2024 Betta Pharmaceuticals Net Income From Continuing Ops quarterly data regression line had arithmetic mean of  317,045,551 and r-squared of  0.04. View All Fundamentals
 
Net Income From Continuing Ops  
First Reported
2018-06-30
Previous Quarter
93.8 M
Current Value
122.3 M
Quarterly Volatility
75.4 M
 
Covid
Check Betta Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Betta Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 32.1 M, Selling General Administrative of 632.6 M or Total Revenue of 1.4 B, as well as many indicators such as . Betta financial statements analysis is a perfect complement when working with Betta Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Betta Pharmaceuticals Technical models . Check out the analysis of Betta Pharmaceuticals Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Betta Stock

Betta Pharmaceuticals financial ratios help investors to determine whether Betta Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Betta with respect to the benefits of owning Betta Pharmaceuticals security.